Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: Evidence from pharmacological inhibition and gene knockout mice

Circulation

Volumn 99, Issue 16, 1999, Pages 2157-2163

  Xi, Lei ^a   Jarrett, Novlet C ^a   Hess, Michael L ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ischemia; Myocardial infarction; Nitric oxide; Pharmacology; Reperfusion

Indexed keywords

ENDOTOXIN; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHORYL LIPID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INDUCTION; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT GENE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033608951     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.16.2157     Document Type: Article

References (40)

1. Kukreja RC, Hess ML. Free Radicals, Cardiovascular Dysfunction and Protection Strategies. Austin, Tex: R.G. Landes Co; 1994.
2. Yoshida K. Maaieh MM, Shipley JB, Doloresco M, Bernardo NL, Qian Y-Z, Elliott GT, Kukreja RC. Monophosphoryl lipid A induces pharmacologic "preconditioning" in rabbit hearts without concomitant expression of 70-kDa heat shock protein. Mol Cell Biochem. 1996;159: 73-80.
3. Elliott GT. Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury. J Mol Cell Cardiol. 1998; 30:3-17.
4. Madonna GS, Peterson JE, Ribi E, Vogel SN. Early phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun. 1986;52:6-11.
5. Henricson BE, Benjamin WR, Vogel SN. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun. 1990;58:2429-2437.
6. Astiz ME, Rackow EC, Still JG, Howell ST, Cato A, Von Eschen KB, Ulrich JT, Rudbach JA, McMahon G, Vargas R. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med. 1995;23:9-17.
7. Kiener PA, Marek F, Rodgers G, Lin P-F, Warr G, Desiderio J. Induction of tumor necrosis factor, IFN-γ, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol. 1988;141:870-874.
8. Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma Interferon, and interkukin-10 mRNA production in murine macrophages. Infect Immun. 1997;65:3239-3247.
9. Myers KR, Beining P, Betts M, Snippe H, Inman J, Golding B. Monophosphoryl lipid A behaves as a T-cell-independent type 1 carrier for hapten-specific antibody responses in mice. Infect Immun. 1995;63:168-174.
10. Takayama K, Qureshi N, Ribi E, Cantrell JL. Use of endotoxin in cancer immunotherapy and characterization of nontoxic but active lipid A components. Am Chem Soc Symp. 1983;231:219-233.
11. Gustafson GL, Rhodes MJ, Hegel T. Monophosphoryl lipid A as a prophylactic for sepsis and septic shock. Prog Clin Biol Res. 1995;392: 567-579.
12. Alving CR. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiol. 1993;187:430-446.
13. Nelson DW, Brown JM, Banerjee A, Bensard DD, Rogers KB, Locke-Winter CR, Anderson BO, Harken AH. Pretreatment with a nontoxic derivative of endotoxin induces functional protection against cardiac ischemia/reperfusion injury. Surgery. 1991;110:365-369.
14. Tosaki A, Maulik N, Elliott GT, Engelman RM, Das DK. Preconditioning of rat heart with monophosphoryl lipid A: a role of nitric oxide. J Pharmacol Exp Ther. 1998;285:1274-1279.
15. Baxter GF, Goodwin RW, Wright MJ, Kerac M, Heads RJ, Yellon DM. Myocardial protection after monophosphoryl lipid A: studies of delayed anti-ischaemic properties in rabbit heart. Br J Pharmacol. 1996;117: 1685-1692.
16. Zhao L, Weber PA, Smith JR, Comerford ML, Elliott GT. Role of inducible nitric oxide synthase in pharmacological "preconditioning" with monophosphoryl lipid A. J Mol Cell Cardiol. 1997;29:1567-1576.
17. Yao Z, Auchampach JA, Pieper GM, Gross GJ. Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. Cardiovasc Res. 1993;27:832-838.
18. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Cardioprotection with ischemic preconditioning and MLA: role of adenosine-regulating enzymes? Am J Physiol. 1996;271:H1004-H1014.
19. Nayeem MA, Elliott GT, Shah MR, Hastillo-Hess SL, Kukreja RC. Monophosphoryl lipid A protects adult rat cardiac myocytes with induction of the 72-kD heat shock protein: a cellular model of pharmacologic preconditioning. J Mol Cell Cardiol. 1997;29:2305-2310.
20. Meng X, Brown JM, Ao L, Nordeen SK, Franklin W, Harken AH, Banerjee A. Endotoxin induces cardiac HSP70 and resistance to endotoxemic myocardial depression in rats. Am J Physiol. 1996;271: C1316-C1324.
21. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298:249-258.
22. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A. 1995;92:10688-10692.
23. Szabo C, Southan GJ, Thiemerman C. Beneficial effects and improved survival in rodent models of septic shock with S-methylthiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci U S A. 1994;91:12472-12476.
24. Xi L, Hess ML, Kukreja RC. Ischemic preconditioning in isolated perfused mouse heart: reduction in infarct size without improvement of post-ischemic ventricular function. Mol Cell Biochem. 1998;186:69-77.
25. Xi L, Chelliah J, Nayeem MA, Levasseur JE, Hess ML, Kukreja RC. Whole body heat shock fails to protect mouse heart against ischemia/ reperfusion injury: role of 72 kDa heat shock protein and antioxidant enzymes. J Mol Cell Cardiol. 1998;30:2213-2227.
26. Maulik N, Engelman DT, Watanabe M, Engelman RM, Maulik G, Cordis GA, Das DK. Nitric oxide signaling in ischemic heart. Cardiovasc Res. 1995;30:593-601.
27. Matheis G, Sherman MP, Buckberg GD, Haybron DM, Young HH, Ignarro LJ. Role of L-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol. 1992;262:H616-H620.
28. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 1992;105:575-580.
29. G-nitro-L-arginine improves myocardial function following ischemia/reperfusion in isolated perfused rat heart. J Mol Cell Cardiol. 1995;27:419-426.
30. Wang P, Zweier JL. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart: evidence for peroxynitrite-mediated reperfusion injury. J Biol Chem. 1996;271:29223-29230.
31. Weiss HR, Rodriguez E, Tse J, Scholz PM. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts. Clin Exp Pharmacol Physiol. 1994;21:607-614.
32. Nakanishi K, Vinten-Johansen J, Lefer DJ, Zhao Z, Fowler WC III, McGee DS, Johnston WE. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol. 1992;263:H1650-H1658.
33. Qiu Y, Rizvi A, Tang X-L, Manchikalapudi S, Takano H, Jadoon AK, Wu W-J, Bolli R. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol. 1997;273: H2931-H2936.
34. Cameron JS, Baghdady R. Role of ATP sensitive potassium channels in long term adaptation to metabolic stress. Cardiovasc Res. 1994;28: 788-796.
35. Cameron JS, Kibler KKA, Berry H, Barron DN, Sodder VH, Barin F. Nitric oxide activates ATP-sensitive potassium channels in hypertrophied ventricular myocytes. FASEB J. 1996;10:A65. Abstract.
36. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992; 70:223-233.
37. ATP channels in rat heart: blockade of ischemic and acetylcholine-mediated preconditioning by glibenclamide. Am J Physiol. 1996;271:H23-H28.
38. ATP channels mediate late preconditioning against infarction produced by monophosphoryl lipid A. Am J Physiol. 1996;27 LH2723-H2729.
39. Elliott GT, Comerford ML, Smith JR, Zhao L. Myocardial ischemia/ reperfusion protection using monophosphoryl lipid A is abrogated by the ATP-sensitive potassium channel blocker, glibenclamide. Cardiovasc Res. 1997;32:1071-1080.
40. ATP channel. J Cardiovasc Pharmacol. 1998;32:337-342.